Group 1 - The third extraordinary general meeting of shareholders was held on November 13, 2025, at the company's conference room in Chongqing [2] - All 12 current directors attended the meeting, along with the board secretary and other senior management [3] - The meeting was convened and presided over by the chairman, Mr. Yu Min, and complied with the relevant provisions of the Company Law and the Articles of Association [2][3] Group 2 - Two non-cumulative voting proposals were reviewed and approved: the proposal to add a director and the proposal to change the registered capital and amend the Articles of Association [4] - The second proposal was a special resolution that required more than two-thirds of the voting rights to pass, which it achieved [5] Group 3 - The meeting was witnessed by lawyers from Taihe Tai (Chongqing) Law Firm, who confirmed that the meeting's procedures and resolutions were in compliance with legal requirements [6]

泰和泰（重庆）律师事务所 关于 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会 之 法律意见书 中国 • 重庆市两江新区财富大道 1 号财富金融中心 36 层 36/F, Fortune Financial Center, No. 1 Fortune Avenue Liangjiang New Area, Chongqing, People's Republic of China 电话| TEL: 86-23-67887666 www.tahota.com 关于 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会 之 法律意见书 （2025）泰律意字（太极集团）第 002 号 致：重庆太极实业（集团）股份有限公司 一、本次股东会的召集、召开程序及召集人资格 （一）经核查，公司于 2025 年 10 月 25 日在《上海证券报》《中 国证券报》《证券时报》《证券日报》和上海证券交易所网站 （www.sse.com.cn）上公告了《重庆太极实业（集团）股份有限公司 关于召开 2025 年第三次临时股东会的通知》（以下简称"《会议通 知》"），该通知公告了本次股东会的召开时间、地点、审议 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 13 日 (二)股东会召开的地点：重庆市渝北区恒山东路 18 号公司 1201 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 630 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 171,633,634 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 31.1258 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 证券代码：600129 证券简称：太极集团 公告编号：2025-086 重庆太极实业（集团）股份有限公司 2025年第三次临时股东会决议公告 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | ...

Summary of Conference Call Records Industry Overview - The pharmaceutical and healthcare sectors are currently experiencing a shift, with companies like沃伍生物, 方盛制药, and 佐力药业 showing strong stock performance and potential investment opportunities due to their solid revenue, profit, and cash flow [1][3] - The medical services industry is facing challenges due to DRG policies and a weak consumer environment, but improvements are expected by 2026 as supply-side constraints and potential mergers or new hospital openings may enhance performance metrics [1][4] Key Companies and Investment Opportunities - **Ophthalmology Sector**: Companies such as 爱尔, 华夏, and 普瑞 are recommended for investment, with expectations of performance release in refractive services by Q1 2026 and improvements in cataract screening next year [1][5] - **Dental Sector**: 通策医疗 is highlighted for its new hospital openings and expected revenue and profit growth in 2026, indicating a turning point for the company [1][6] - **Pharmaceutical Companies**: 流感-related companies like 国邦, 普洛药业, and 联邦制药 are experiencing high capacity utilization and are expected to see significant growth in Q4 and Q1 due to potential shortages and price increases [2][12] Market Trends and Predictions - The blood products industry is consolidating, with a focus on mergers and acquisitions, which may stabilize product prices and enhance demand in the context of flu outbreaks [8] - The vaccine industry is poised for growth with key players like 康华生物 and 康希诺 expected to release significant data and products in 2026, which could drive market interest [9][10] - The traditional Chinese medicine sector is forecasted to recover, with a focus on innovative drug companies and OTC brands that are well-positioned for growth [13] Retail Pharmacy Sector - The retail pharmacy sector is expected to benefit from consolidation as smaller chains face operational pressures, allowing leading companies like 益丰, 大森林, and 老百姓 to capitalize on improved consumer conditions and policy support [14] Conclusion - The overall sentiment in the pharmaceutical and healthcare sectors is cautiously optimistic, with several companies positioned for growth amid a backdrop of regulatory changes and market dynamics. Investors are encouraged to focus on companies with strong fundamentals and growth potential in the coming years [1][3][4][12][14]

Group 1 - The company stated that its stock price is influenced by various factors, including internal factors such as operational performance and development potential, as well as external factors like macroeconomic conditions, market fluctuations, and investor confidence [2] - The company emphasized its commitment to fulfilling information disclosure obligations in accordance with the relevant requirements of the Shanghai Stock Exchange [2]

Core Viewpoint - Taiji Group emphasizes its commitment to maintaining shareholder interests and enhancing investor confidence through strategic actions in the capital market [2] Group 1: Company Actions - The company held the 30th meeting of the 10th Board of Directors on July 16, 2025, and the second extraordinary general meeting of shareholders on August 6, 2025, to review and approve relevant proposals [2] - On September 22, 2025, the company completed a share buyback, utilizing a total of 120 million yuan [2] Group 2: Future Plans - The company plans to consider various factors such as market conditions, regulatory requirements, and investor needs to fulfill its responsibilities as a listed company [2] - Taiji Group aims to strengthen compliance information disclosure, focus on the pharmaceutical and health sector, accelerate technological innovation, improve corporate governance, and enhance investor relations management [2]

Core Viewpoint - Taiji Group emphasizes the importance of market capitalization management, which includes governance standardization, value creation enhancement, quality information disclosure, investor relations management, and reasonable shareholder dividend policies [2]. Group 1 - The company aims to consider various factors such as market conditions, regulatory requirements, and investor needs in its capital market performance [2]. - The goal is to "improve quality and efficiency while returning value" to actively protect investor rights [2]. - The company encourages stakeholders to pay attention to its announcements for specific updates [2].

Core Viewpoint - Taiji Group focuses on the production and sales of traditional Chinese and Western medicine, emphasizing key areas in health products and a diverse product matrix [2] Company Overview - The company operates in the "4+1" key areas: digestive metabolism medications, respiratory antibiotics, cardiovascular drugs, and narcotic anti-tumor medications, along with health products [2] - Notable products include: - Digestive metabolism: Taiji Huoxiang Zhengqi Oral Liquid, Tai Luo [2] - Respiratory antibiotics: Acute Support Syrup, Sinusitis Oral Liquid [2] - Cardiovascular: Tongtian Oral Liquid, Danshen Oral Liquid [2] - Narcotic anti-tumor: Morphine Sustained Release Tablets, Lofentanil Sustained Release Tablets, Xiaojin Tablets [2] - The health product matrix includes high-end refined medicinal slices and various derivative products such as herbal teas and throat lozenges [2]

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the traditional Chinese medicine sector [6]. Core Insights - The traditional Chinese medicine sector showed resilience with a 0.81% increase in the index, while the broader pharmaceutical sector declined by 2.4% [2]. - The price-to-earnings (PE) ratio for the traditional Chinese medicine sector is 28.11X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.37X, also showing a minor rise [3]. - The recent price index for traditional Chinese medicinal materials has increased by 0.2%, indicating a slight upward trend in the market [4]. - The fourth batch of national procurement for traditional Chinese medicine has been announced, including 90 varieties, which presents both challenges and opportunities for production companies [5]. Summary by Sections Market Performance - The traditional Chinese medicine index closed at 6593.95 points, with a weekly increase of 0.81%, contrasting with declines in other pharmaceutical sectors [2][11]. - Notable performers in the sector include ST HuLuWa, DaRenTang, and ZhongSheng Pharmaceutical, while companies like WanBangDe and QiDi Pharmaceutical lagged [2]. Valuation - The PE ratio for the traditional Chinese medicine sector is currently at 28.11X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [3]. - The PB ratio is at 2.37X, with a maximum of 2.59X and a minimum of 2.17X over the past year [3]. Raw Material Prices - The price index for traditional Chinese medicinal materials has shown a slight increase, with 9 categories rising and 3 falling in the past week [4]. Focus on National Procurement - The fourth batch of national procurement includes 90 varieties, with a focus on products that have significant demand and established clinical applications [5]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [6][9]. - Specific recommendations include companies with strong R&D capabilities, those less affected by procurement impacts, and leading brand enterprises in traditional Chinese medicine [9].

重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会会议资料 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会资料 2025 年 11 月 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会会议资料 目录 一、关于增补公司董事的议案...................................3 二、关于变更注册资本暨修订《公司章程》的议案.......... 4 1 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会会议资料 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会议程 重庆太极实业（集团）股份有限公司 2025 年 11 月 13 日 2 一、主持人宣布会议开始； 二、主持人报告股东现场到会情况； 三、到会股东审议如下议案： 1.关于增补公司董事的议案； 2.关于变更注册资本暨修订《公司章程》的议案。 四、会议讨论； 五、股东及其委托代理人对相关议案投票表决； 六、表决统计； 七、见证律师宣读法律意见书； 八、到会董事在会议决议上签字； 九、主持人宣布会议结束。 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会会议 ...